Trial Profile
Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Oct 2021
Price :
$35
*
At a glance
- Drugs Solanezumab (Primary) ; Florbetapir F 18
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms EXPEDITION-2
- Sponsors Eli Lilly and Company
- 30 Jul 2021 Results from ENGAGE, EMERGE, Expedition 1, 2, and 3 and the PRIME study; combining evidence across outcomes and trials using bayesian hierarchical analysis, presented at the Alzheimer's Association International Conference 2021
- 31 Jul 2020 Results of post hoc analysis from EXPEDITION-1 and EXPEDITION-2 presented at the Alzheimer's Association International Conference 2020
- 20 Jul 2017 Results of PK/PD model development and evaluation using patient data from NCT00905372, NCT00904683, NCT01900665 trials presented at the Alzheimer's Association International Conference 2017